ANIP FY 2024 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

FY 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$614M+26.2% YoY

Gross Profit

$364M59.3% margin

Operating Income

$584,0000.1% margin

Net Income

-$19M-3.0% margin

EPS (Diluted)

$-1.04

Cash Flow

Operating Cash Flow

$64M

Free Cash Flow

$47M

Stock-Based Comp.

$29M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$855M

Stockholders' Equity

$429M

Cash & Equivalents

$145M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$614M	$487M	+26.2%
Gross Profit	$364M	$305M	+19.3%
Operating Income	$584,000	$47M	-98.8%
Net Income	-$19M	$19M	-198.6%